2016 Innovation Coast Competition Result

Results of 2016 Innovation Coast Competition

First place-$20,000

John Pham, DDS, MS
University of Southern California

InBrace is an orthodontic solution that combines the effectiveness of conventional braces, the aesthetics of behind-the-teeth braces, and the comfort and ease of Invisalign all in a single appliance. Through a joint collaboration between USC's top engineers and orthodontists, we've developed a process that programs shape memory alloy to deliver an orthodontic treatment that is faster, more effective, and more hygienic than any current solution.

Second place-$15,000
BLITAB Technology Ltd.

Kristina Tsvetanova
Vienna, Austria

BLITAB Technology Ltd. developed the World's first tactile tablet, using a revolutionary new liquid-based technology to create tactile relief outputting braille, graphics and maps for the blind and partially sighted. We call it BLITAB® – the "iPad" for the blind.

BLITAB® is the first-ever Braille tablet, using an innovative exponential technology to create tactile relief outputting braille, graphics and maps for blind and partially sighted people. It is a next generation affordable multi-functional device for Braille reading and writing that displays one whole page Braille text, without any mechanical elements. For the first time tactile graphics can be output on a digital device and this opens a complete new world of content. BLITAB® brings a tremendous positive change in access to graphics and tactile media at minimal end user costs and changes the leisure, educational and life experience of blind and visually impaired.

Third place-$10,000

Niki Bayat, PhD Student, Chemical Engineering
Jessica Golden, PhD Student, Chemistry
University of Southern California

AesculaTech was founded by a team of highly skilled scientists and an ophthalmologist developing a platform of thermally responsive materials for sustained, localized drug delivery therapies. Toward this goal, AesculaTech is developing AesculaGel, a thermally responsive hydrogel used for sustained release of prostaglandin analogs for the treatment of glaucoma. Ophthalmologists, researchers, and industry contacts, who are deeply concerned by limited patient compliance with ophthalmic pharmaceutical treatment, immediately validated this course of action. In 2010 there were 60.5 million glaucoma patients worldwide, and the pharmaceutical market for glaucoma treatment was worth over $5.1 billion. Currently, the most widely used method of treatment for glaucoma is the daily application of eye drops. AesculaGel eliminates the need for daily dosing and ensures patient compliance by delivering medication to the ocular surface continuously for 90 days through a non-invasive method. This technology will be developed through preclinical studies and clinical trials to an FDA market approved product.